08:00 , Jan 22, 2002 |  BC Week In Review  |  Clinical News

Cytolin: AMUN started a U.S. dose-escalating Phase Ib trial of Cytolin in 13 HIV patients.

Amerimmune Pharmaceuticals Inc. (AMUN), Woodland Hills, Calif.   Product: Cytolin   Business: Infectious diseases   Therapeutic category: Antibody, Immune modulation   Target: Adhesion molecules on immune cells   Description: Murine monoclonal antibody targeted against adhesion...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

Cytolin: Phase Ia

AMUN said results of an open-label U.S. trial showed Cytolin was well tolerated in 13 patients at doses of 0.05 mg/kg and 0.10 mg/kg. No serious adverse events were reported. Amerimmune Pharmaceuticals Inc. (AMUN), Woodland...
08:00 , Mar 13, 2000 |  BC Week In Review  |  Clinical News

Cytolin: Began Phase I/II trial

(Board and management, B8 and B9) Amerimmune Pharmaceuticals Inc., Los Angeles, Calif.   Product: Cytolin   Business: Infectious diseases   Therapeutic category: Antibody, Immune modulation   Target: Adhesion molecules on immune cells   Description: Monoclonal...
08:00 , Mar 13, 2000 |  BC Week In Review  |  Company News

Amerimmune board of directors update

(Management, B9) Amerimmune Inc., Los Angeles, Calif.   Business: Infectious diseases   Resigned: Daniel Azarnoff and Roy Azarnoff  ...
08:00 , Mar 13, 2000 |  BC Week In Review  |  Company News

Amerimmune management update

(Board, B8) Amerimmune Inc., Los Angeles, Calif.   Business: Infectious diseases   Hired: Deborah Garrett Kalof as CFO, formerly consultant to Bastion Capital Fund LLP; Kalof replaces Wellington Ewen  ...
07:00 , Aug 9, 1999 |  BC Week In Review  |  Clinical News

Cytolin: Began Phase I/II trial

Amerimmune Inc. , Los Angeles, Calif.   Product: Cytolin   Business: Infectious diseases   Therapeutic category: Antibody, Immune modulation   Target: Adhesion molecules on immune cells   Description: Monoclonal antibody against immune cell adhesion molecules...